glp 1 thyroid cancer risk of medullary with GLP-1 receptor agonist use for more than year may increase GLP-1 Receptor Agonists and Thyroid – Do GLP-1s cause thyroid cancer?

Researchers recruited 338 adults who had a BMI over 30 or a BMI of 2730 with one or more weight-related conditions and were assigned to one of the following experimental groups or a placebo group: 1 mg of subcutaneous retatrutide 4 mg of subcutaneous retatrutide, starting at an initial dose of 2 mg 4 mg of subcutaneous retatrutide, starting at an initial dose of 4 mg 8 mg of subcutaneous retatrutide, starting at an initial dose of 2 mg 8 mg of subcutaneous retatrutide, starting at an initial dose of 4 mg 12 mg of subcutaneous retatrutide, starting at an initial dose of 2 mg The trials promising results pave the way for further phase 3 research to evaluate retatrutides efficacy in comprehensive obesity management and its impact on associated health issues

53 HuiY.WangD.LiW.ZhangL.JinJ.MaN.et al (2011)

They operate at the level of individual receptors, growth factors, and gene expression pathways

Cascella R, Evangelisti E, Zampagni M, Becatti M, DAdamio G, Goti A, Liguri G, Fiorillo C, Cecchi C

In these cases, a highly bioavailable liposomal supplement can help bridge the gap